Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial (ECLIPSE)

  • End date
    Dec 31, 2024
  • participants needed
  • sponsor
    Cardiovascular Systems Inc
Updated on 20 October 2022
heart disease
angina pectoris
unstable angina
acute coronary syndrome
coronary angioplasty


This trial will evaluate Orbital Atherectomy compared to conventional balloon angioplasty technique for the treatment of severely calcified lesions prior to implantation of drug-eluting stents (DES).

Condition Coronary Artery Disease, Ischemic Heart Disease, Non ST Segment Elevation Myocardial Infarction
Treatment Orbital Atherectomy, Balloon, Balloon
Clinical Study IdentifierNCT03108456
SponsorCardiovascular Systems Inc
Last Modified on20 October 2022


Yes No Not Sure

Inclusion Criteria

Subject is 18 years of age or older
Subject presents with
stable ischemic heart disease or
acute coronary syndrome (NSTEMI or unstable angina), or
stabilized recent STEMI (>48 hours prior to randomization procedure)
Subject has signed the Institutional Review Board (IRB) or Ethics Committee (EC)
approved ECLIPSE trial Informed Consent Form (ICF) prior to any trial related

Exclusion Criteria

Subject has a history of any cognitive or mental health status that would interfere with trial participation
Subject is participating in or has plans to participate in any other investigational drug or device trial that has not reached its primary endpoint
Subject is a female who is pregnant
Subject is receiving or scheduled to receive chemotherapy within thirty (30) days prior or any time after the randomization procedure
Subject has undergone any prior PCI in the target vessel or its branches 12 months prior to randomization
Subject has undergone a PCI procedure that is unsuccessful or with complications within 30 days prior to randomization, including during the randomization procedure
Subject has a life expectancy of ≤ 12 months
Any cardiac intervention or cardiac surgery planned within 12 months post randomization procedure aside from a potential planned staged PCI as part of the randomized treatment strategy
Subject has major valve disease and underwent intervention within 30 days prior to randomization
Subject has received a heart transplant
Evidence of heart failure by at least one of the following (heart failure assessment is not required per protocol but must be reviewed prior to enrollment if data is available)
Current heart failure defined as dyspnea at rest (NYHA class IV assessed day of procedure), or
Most recent LVEF ≤25%, or
Subject has a known sensitivity to contrast media, which cannot be adequately pre-medicated
Killip class ≥2 (post STEMI patients)
Subject has a relative or absolute contraindication to dual antiplatelet therapy or (for patients with atrial fibrillation) single antiplatelet therapy (P2Y12 inhibitor preferred) with an anticoagulant for at least 6 months after PCI
Planned use in the randomized lesion(s) of a bare metal stent (BMS), bioresorbable
Subject has a history of a stroke or transient ischemic attack (TIA) within six (6) months prior to randomization, or any permanent neurologic deficit
scaffold (BRS), non-stent treatment only
Subject has a history of bleeding diathesis or coagulopathy or intention to refuse blood transfusion if one should become necessary
Subject has evidence of an active infection on the day of the randomization procedure requiring oral or intravenous antibiotics
Subject with known allergy to atherectomy lubricant components including soybean oil, egg yolk phospholipids, glycerin and sodium hydroxide
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note